POINT-Logo-Colour (blue).png
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
August 08, 2022 08:30 ET | POINT Biopharma
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at...
ITM_Logo_Claim_RGB_high-res.png
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
July 21, 2022 05:21 ET | ITM Isotope Technologies Munich SE
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...
POINT-Logo-Colour (blue).png
POINT Biopharma to Participate in Upcoming Investor Conferences
July 06, 2022 08:30 ET | POINT Biopharma
INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
ITM_Logo_Claim_RGB_high-res.png
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
June 21, 2022 11:45 ET | ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...
POINT-Logo-Colour (1).png
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
June 21, 2022 08:30 ET | POINT Biopharma
Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer...
POINT-Logo-Colour (1).png
POINT Biopharma to Participate in Upcoming Investor Conferences
May 19, 2022 17:30 ET | POINT Biopharma
INDIANAPOLIS, May 19, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (1).png
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
May 16, 2022 08:30 ET | POINT Biopharma
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy INDIANAPOLIS,...
POINT-Logo-Colour (1).png
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
May 13, 2022 08:30 ET | POINT Biopharma
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada...
POINT-Logo-Colour (1).png
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
May 05, 2022 09:15 ET | POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT-Logo-Colour (1).png
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
April 26, 2022 08:30 ET | POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...